{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T02:57:34Z","timestamp":1720493854193},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00277-013-1920-0","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T05:55:32Z","timestamp":1383112532000},"page":"609-616","source":"Crossref","is-referenced-by-count":3,"title":["A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms"],"prefix":"10.1007","volume":"93","author":[{"given":"Francesca","family":"Fantasia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma Nora","family":"Di Capua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Cenfra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mecarocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Rago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Cotroneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Busanello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Equitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lo-Coco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Nervi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"key":"1920_CR1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","volume":"108","author":"C Lacout","year":"2006","unstructured":"Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652\u20131660","journal-title":"Blood"},{"key":"1920_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e328343998e","volume":"18","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O (2011) Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 18:117\u2013123","journal-title":"Curr Opin Hematol"},{"key":"1920_CR3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","volume":"118","author":"T Klampfl","year":"2011","unstructured":"Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, J\u00e4ger R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R (2011) Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 118:167\u2013176","journal-title":"Blood"},{"key":"1920_CR4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118:1723\u20131735","journal-title":"Blood"},{"key":"1920_CR5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bcmd.2012.11.009","volume":"50","author":"H Zhan","year":"2013","unstructured":"Zhan H, Cardozo C, Yu W, Wang A, Moliterno AR, Dang CV, Spivak JL (2013) MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol Dis 50:190\u2013195","journal-title":"Blood Cells Mol Dis"},{"key":"1920_CR6","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","volume":"107","author":"AI Shafer","year":"2006","unstructured":"Shafer AI (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107:4214\u20134222","journal-title":"Blood"},{"key":"1920_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2008.001271","volume":"94","author":"F Passamonti","year":"2009","unstructured":"Passamonti F, Rumi E (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94:7\u201310","journal-title":"Haematologica"},{"key":"1920_CR8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2217\/fon.12.50","volume":"8","author":"AM Vannucchi","year":"2012","unstructured":"Vannucchi AM, Pieri L, Susini MC, Guglielmelli P (2012) BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncol 8:575\u2013593","journal-title":"Future Oncol"},{"key":"1920_CR9","first-page":"512","volume":"8","author":"HR Kim","year":"2013","unstructured":"Kim HR, Choi HJ, Kim YK, Kim HJ, Shin JH, Suh SP, Ryang DW, Shin MG (2013) Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms. PLoS ONE 8:512\u2013518","journal-title":"PLoS ONE"},{"key":"1920_CR10","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788\u201322792","journal-title":"J Biol Chem"},{"key":"1920_CR11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.leu.2404209","volume":"20","author":"AM Vannucchi","year":"2006","unstructured":"Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P (2006) A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 20:1055\u20131060","journal-title":"Leukemia"},{"key":"1920_CR12","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-11-123810","volume":"111","author":"RC Skoda","year":"2008","unstructured":"Skoda RC, Tiedt R, Hao-Shen H, Sobas M, Looser R, Dirnhofer S, Schwaller J (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD and phenotypes in transgenic mice. Blood 111:3931\u20133940","journal-title":"Blood"},{"key":"1920_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-009-0005-6","volume":"4","author":"J Thiele","year":"2009","unstructured":"Thiele J, Kvasnicka HM (2009) The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malignancy Rep 4:33\u201340","journal-title":"Curr Hematol Malignancy Rep"},{"key":"1920_CR14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156\u2013159","journal-title":"Anal Biochem"},{"key":"1920_CR15","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.leu.2403448","volume":"18","author":"L Elia","year":"2004","unstructured":"Elia L, Gottardi E, Floriddia G, Grillo R, Ciambelli F, Luciani M, Chiusolo P, Invernizzi R, Meloni G, Fo\u00e0 R, Saglio G, Cimino G (2004) Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. Leukemia 18:1824\u20131830","journal-title":"Leukemia"},{"key":"1920_CR16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell P, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"1920_CR17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2010.090068","volume":"12","author":"JD Merker","year":"2010","unstructured":"Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder L (2010) Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 12:58\u201364","journal-title":"J Mol Diagn"},{"key":"1920_CR18","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VHJ, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe Against Cancer program. Leukemia 17:2474\u20132486","journal-title":"Leukemia"},{"key":"1920_CR19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","volume":"94","author":"E Lippert","year":"2009","unstructured":"Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kr\u00f6ger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94:38\u201345","journal-title":"Haematologica"},{"key":"1920_CR20","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","volume":"27","author":"JV Jovanovic","year":"2013","unstructured":"Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, OppligerLeibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D (2013) Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European Leukemia Net\/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27:2032\u20132039","journal-title":"Leukemia"},{"key":"1920_CR21","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"1920_CR22","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cav\u00e9 H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonz\u00e1lez M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer Program. Leukemia 17:2318\u20132357","journal-title":"Leukemia"},{"key":"1920_CR23","doi-asserted-by":"crossref","first-page":"2214822","DOI":"10.1371\/journal.pone.0022148","volume":"6","author":"T Irino","year":"2011","unstructured":"Irino T, Uemura M, Yamane H, Umemura S, Utsumi T, Kakazu N, Shirakawa T, Ito M, Suzuki T, Kinoshita K (2011) JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients. PloS ONE 6:2214822","journal-title":"PloS ONE"},{"key":"1920_CR24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1532\/IJH97.05051","volume":"81","author":"S Koschmieder","year":"2005","unstructured":"Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG (2005) Role of transcription factors C\/EBPalpha and PU.1 in normal hematopoiesis and leukemia. Int J Hematol 81:368\u2013377","journal-title":"Int J Hematol"},{"key":"1920_CR25","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110:4030\u20134036","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1920-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1920-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1920-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T14:13:25Z","timestamp":1551190405000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1920-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1920-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}